---
title: "PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)"
description: "This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the treatment of patients with advanced solid malignancies or non-Hodg"
url: "https://www.clareohealth.com/clinical-trials/NCT02702492"
---

This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the treatment of patients with advanced solid malignancies or non-Hodgkin's lymphoma (NHL).

## Key Facts

**ID:** NCT02702492
**Status:** TERMINATED
**Phase:** PHASE1
**Type:** INTERVENTIONAL
**Enrollment:** 60
**Sponsor:** Karyopharm Therapeutics Inc

## About This Study

This clinical trial was testing KPT-9274, a new oral treatment, for patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL) who have already tried other treatments. The study aimed to see how safe and effective this drug is for these patients.

## Detailed Description

This is a first-in-human, multi-center, open-label clinical study with separate Dose Escalation and Expansion Phases to assess preliminary safety, tolerability, and efficacy of KPT-9274, a dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies (including sarcoma, colon, lung, melanoma, etc.) or NHL for which all standard therapeutic options considered useful by the investigator have been exhausted.

## Conditions

- Solid Tumors
- NHL

## Interventions

**DRUG: KPT-9274**


**DRUG: Niacin ER**


**DRUG: Nivolumab**


## Eligibility

Inclusion Criteria: Participants must meet all of the following inclusion criteria to be eligible to enroll in the Part C of this study. 1.

## Who Can Participate

**Minimum age:** 18

**Sex:** ALL

**Accepts healthy volunteers:** No

## Study Locations

- UCLA Health, Los Angeles, California, United States
- University of Colorado Cancer Center, Aurora, Colorado, United States
- Georgetown University, Lombardi Comprehensive Cancer Center, Washington D.C., District of Columbia, United States
- Mayo Clinic Rochester, Rochester, Minnesota, United States
- NYU-Laura & Isaac Perlmutter Cancer Center, New York, New York, United States
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Princess Margaret Hospital, Toronto, Ontario, Canada

## Contact Information

## Important Dates

**Study start:** June 8, 2016

**Completion date:** January 26, 2021

**Last updated:** November 25, 2024

## Consider Discussing with Your Care Team

### Worth Discussing If

- You have advanced solid tumors or non-Hodgkin's lymphoma that have not responded to previous treatments.
- Your doctor has suggested exploring new treatment options after exhausting standard therapies.
- You are looking for a clinical trial that might offer access to a new medication.

### Questions to Ask

- What are the potential side effects of KPT-9274?
- How does this treatment compare to my current options?
- What are the eligibility requirements for this trial?
- How often would I need to visit the clinic if I participate?
- What should I expect during the treatment process?
- Are there any risks associated with being in this trial?

[View on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02702492)
